The increased use of split-liver transplantation (SLT) represents a strategy to increase the supply of organs. Although outcomes after SLT and whole liver transplantation (WLT) are similar on average among pediatric recipients, we hypothesized that the relationship between graft type and outcomes may vary depending on patient, donor, and surgical characteristics. We evaluated graft survival among pediatric (<18 years) deceased donor, liver-only transplant recipients from March 2002 until December 2015 using data from the Scientific Registry of Transplant Recipients. Graft survival was assessed in a Cox proportional hazards model, with and without effect modification between graft type and donor, recipient, and surgical characteristics, to identify conditions where the risk of graft loss for SLT and WLT were similar. In a traditional multivariable model, characteristics associated with graft loss included donor age >50 years, recipient weight <10 kg, acute hepatic necrosis, autoimmune diseases, tumor, public insurance, and cold ischemia time (CIT) >8 hours. In an analysis that explored whether these characteristics modified the relationship between graft type and graft loss, many characteristics associated with loss actually had similar outcomes regardless of graft type, including weight <10 kg, acute hepatic necrosis, autoimmune diseases, and tumor. In contrast, several subgroups had worse outcomes when SLT was used, including recipient weight 10-35 kg, non-biliary atresia cholestasis, and metabolic disease. Allocation score, share type, or CIT did not modify risk of graft type and graft failure. Although one might anticipate that individuals with higher rates of graft loss would be worse candidates for SLT, data suggest that these patients actually have similar rates of graft loss. These findings can guide surgical decision making and may support policy changes that promote the increased use of SLT for specific pediatric recipients.
Pediatric liver transplantation (LT) provides lifesaving therapy for children with end-stage liver disease and other metabolic conditions but continues to be hindered by a scarcity of available organs. (1) Wait-listed children typically receive fewer offers for deceased donor organs than adults, suggesting that they are especially vulnerable to an imbalance in need and availability. (2) Consequently, neonates have the highest rate of wait-list mortality for any age group with nearly one-third of wait-listed neonates dying before receiving a suitable offer. (3) The use of split-liver transplantation (SLT) represents an opportunity to increase the supply of organs and has the potential to shorten wait-list times and decrease pretransplant morbidity and mortality, particularly for children. Recent evidence suggests that outcomes following SLT are now likely comparable to whole liver transplantation (WLT) for both pediatric and adult recipients. (4) (5) (6) At the same time, the benefits of SLT may vary among patients with different donor, recipient, or surgical characteristics. For example, a study of adult transplant recipients concluded that graft failure following SLT and WLT was equivalent on average but that status 1 recipients had poorer outcomes when receiving SLT compared with WLT. (5) Analyses of recipient, donor, and surgical characteristics can serve to identify optimal individuals for higher-risk organs who are not at increased risk of graft loss as well as suboptimal recipients for whom whole livers would yield better outcomes. (7) In pediatric LT, several donor, recipient, and surgical characteristics have been shown to influence outcomes, such as donor age, cause of death, fulminant disease in the recipient, and prolonged cold ischemia time (CIT). (8, 9) As with adults, these characteristics may yield subgroups of pediatric candidates whose outcomes are worse when receiving SLT, and other groups for whom outcomes are not affected by graft type. Having a better understanding of which characteristics are modified by graft type would serve to better inform surgical decision making about which recipients are appropriate for SLT and could potentially inform policy to promote SLT. In this study, we used a large national registry to explore which characteristics modify the association between graft type and graft failure among pediatric deceased organ recipients in order to better understand the opportunities to expand the organ supply through further use of SLT.
Patients and Methods

Data sOurce
This study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donors, wait-listed candidates, and transplant recipients in the United States, submitted by the members of the Organ Procurement and Transplantation Network (OPTN) and described elsewhere. (10) The Health Resources and Services Administration, US Department of Health and Human Services, provides oversight to the activities of the OPTN and SRTR contractors.
stuDY pOpulatiOn
We identified 5345 pediatric liver-only, first-time transplant recipients of a deceased WLT or SLT who received an organ between March 1, 2002 (ie, after implementation of the Pediatric End-Stage Liver Disease (PELD)/ Model for End-Stage Liver Disease [MELD] system) and December 31, 2015; patients with missing weight (n = 1) or missing CIT (n = 284) were excluded. We compared donor, recipient, and surgical characteristics between recipients of WLT and SLT using chi-square tests.
graFt tYpe
All individuals were defined as having an SLT if they received a portion of a deceased donor graft. Sensitivity analyses exploring the impact of organs used by 1 recipient (ie, "cut down") versus 2 recipients and in vivo versus ex vivo splits showed no difference in graft failure, a finding consistent with other studies demonstrating similar occurrence of graft failure, biliary strictures, and vascular thromboses. (5, 11) graFt survival Graft failure was identified as any reported graft failure or death (ie, "all-cause graft loss"). "All-cause graft loss" means that:
1. All deaths are attributed to a graft failure, but not all graft failure leads to death. 2. Risk of graft failure is always greater than risk of death.
The functional form for recipient, donor, and surgical characteristics were explored using Kaplan-Meier curves and log-rank tests. We used Cox proportional
Original article | 121 hazards models to characterize the association between allograft type and graft survival after adjustment for the following variables: donor age and race, cause of death, recipient weight at transplant, recipient sex, recipient race/ethnicity, underlying disease, laboratory PELD/MELD at transplant, status 1 designation, insurance type, CIT, and share type (ie, local, regional, or national). The decision to include these specific variables in the final model for multivariable regression was derived from associations between covariates with risk factors and the outcome in both the published literature as well as statistical tests within this cohort. (8) Recipients were censored upon retransplantation or multiorgan transplantation (eg, liver-kidney).
eFFect MODiFicatiOn
To identify specific recipient, donor, and surgical characteristics that modify the effect of allograft type on graft survival, we performed Cox regression analysis with effect modification between allograft type with additional covariates. Only those covariates for which there existed an a priori hypothesis and in which the relationship between graft type and outcome may be modified were included in the analysis. Test for effect modification was assessed in an unadjusted analysis as well as a parsimonious model that adjusted for donor cause of death, recipient weight, recipient diagnosis, allocation score, share type, and CIT as previously described. (7) Donor age was excluded from the effect modification analysis given the small number of individuals receiving a split from a donor >50 years (n < 100). Donor race, recipient race, and recipient insurance were excluded because there was no a priori reason to consider that the association between allograft type and graft failure would vary by these characteristics. From this model, the relative impact of SLT versus WLT could be evaluated with factors that exacerbated the impact of SLT versus WLT being defined as "optimal," whereas those that had no impact (or attenuated the impact) on SLT versus WLT were defined as "suboptimal."
pOtential FOr increaseD slt
In order to further quantify opportunities to increase the use of SLT among pediatric LT candidates, we identified the number of wait-listed individuals who died or were delisted because of medical unsuitability or declining health, having been on the waiting list for at least 7 days in the period from March 1, 2002, to December 31, 2016 (n = 1160). Because it can be reasonably assumed that individuals would only be listed if they were appropriate candidates for transplant, individuals delisted 7 days later due to death or medical unsuitability represent instances where an offer through SLT would have benefited the candidates. The number of individuals with optimal characteristics who were listed but then delisted served to provide an estimate of the potential reduction in waitlist mortality that may have occurred if a greater use of SLT had occurred.
statistical analYsis
All tests were 2-sided with statistical significance set at alpha = 0.05. Confidence intervals (CIs) are reported using the method of Louis and Zeger, as previously reported. (12) All analyses were performed using STATA 14.0 (Stata Corp., College Station, TX). This study was approved by the institutional review board of Johns Hopkins University School of Medicine. No organs were used from executed prisoners.
Results
patient cHaracteristics
Among 5345 pediatric recipients in our study, 1694 (31.7%) received an SLT and 3651 (68.3%) received a WLT (Table 1) . SLT recipients were less likely than WLT recipients to have a donor who was <18 years (59.5% for SLT and 84.3% for WLT) and more likely to have a donor between 18 and 50 years (38.7% versus 13.6%; P < 0.001). SLT recipients were less likely to have a donor with anoxia (19.5% versus 35.1%) and more likely that the donor had head trauma (63.1% versus 49.8%; P < 0.001). A larger percentage of SLT recipients were <10 kg (51.7% versus 32.9%; P < 0.001), had biliary atresia (BA; 44.2% versus 36.0%; P < 0.001), and were status 1 (37.7% versus 31.2%; P < 0.001). SLT recipients were less likely to receive the organ from a national share (4.7% versus 23.5%; P < 0.001), but CIT did not vary between the 2 graft types.
graFt Failure
Although SLT was associated with increased graft failure in an unadjusted model (hazard ratio [HR], 1.17; 95% CI, 1.03-1.33), there was no evidence of increased risk after adjustment for confounding donor, recipient, and surgical characteristics on average 
eFFect MODiFicatiOn
To determine if specific characteristics modified the effect between graft type and graft failure, several variables were tested in unadjusted and adjusted models. In these models, a coefficient of 1 (or a nonsignificant coefficient at the 95% confidence level) indicates that for individuals within that subcohort, the risk of graft failure did not vary between individuals receiving an SLT or WLT (Fig. 1) . Alternatively, a coefficient of 1.4 means that among individuals with that specific characteristic (eg, a specific weight category), individuals who received a SLT had 1.4 times the risk of graft failure than individuals with a WLT. In general, subcohorts with the highest overall graft failure were not further negatively impacted by having an SLT versus WLT, and therefore would be optimal candidates; in contrast, recipients with overall favorable outcomes who had higher rates of graft failure with SLT compared with WLT would be suboptimal candidates. For example, recipient weight <10 kg was associated with increased graft failure in general ( 
pOtential FOr increaseD slt
For those characteristics in which some subcohorts were optimal (ie, weight < 10 kg; all recipient diagnoses except non-BA cholestasis and metabolic disorder), we identified the number of recipients who were wait-listed for at least 7 days but ultimately died or were delisted because of medical unsuitability while waiting for an offer over the study period (ie, 178 months; n = 1160). Among wait-list deaths, 451 pediatric candidates were <10 kg and 348 (77.2%) were on the waiting list for at least 7 days before death or delisting due to poor health, indicating that as many as approximately 23 candidates per year may likely have benefitted from increased availability of SLT. Furthermore, within this group of 348 pediatric candidates, 320 (92%) had optimal underlying conditions and 28 had suboptimal conditions (ie, 13 with non-BA neonatal cholestasis and 15 with metabolic disorders) indicating that as many as 22 children per year with optimal weight and underlying disease died after waiting at least 7 days for an organ and would likely have benefited from increased use of SLT.
Discussion
Increasing evidence suggests that outcomes following SLT and WLT are similar. (4) (5) (6) 13) However, this assessment should not be taken to indicate that risk of graft failure is equivalent for all subgroups of patients.
Although there may be a tendency by health care providers to anticipate that the sickest children with the highest rates of pretransplant mortality (eg, PELD/ MELD ≥30 or status 1) would be relatively poorer candidates for SLT and have worse outcomes, our findings from this national study of 5345 pediatric recipients indicate that the opposite is true. Specifically, characteristics associated with overall higher rates of graft failure (eg, recipient weight <10 kg; recipient diagnosis of acute hepatic necrosis, autoimmune disorders, or tumor; and CIT ≥ 8 hours) had equivalent risk of graft failure among SLT recipients when compared with WLT. At the same time, pediatric recipients with the lowest overall risk of graft failure (eg, recipient weight 10-35 kg; non-BA congenital cholestasis; metabolic disorders; CIT <8 hours) fared worse when they received a SLT compared with WLT. These findings were independent of pretransplant mortality risk as determined by PELD/MELD. Our findings that graft failure among children <10 kg and those with status 1 are not adversely impacted by the type of deceased donor allograft type dovetails with the fact that patients with these characteristics are also recipients with the highest rates of death while awaiting LT. (1, 14) Consequently, our findings strengthen the argument that there should be broader use of SLT for these fragile subgroups of children and that such a practice, and policy, would likely translate to important reductions in wait-list death, the stated goal of our current allocation system. (15) Notably, broader geographic sharing, including national sharing, was not associated with worse outcomes for children. Our analysis also attempted to quantify the degree to which increased use of SLT could potentially reduce wait-list mortality and determined that most children who die on the waiting list were waiting for at least a week, and approximately half of these children met criteria for being an optimal recipient for SLT with a predicted graft survival that would be similar for SLT and WLT. These findings should be considered in the context of work by Hsu et al. that showed nearly half of the children who died on the waiting list never received a single offer of a liver. (2) Furthermore, recent research by Perito et al. showed that approximately half of the most splitable livers, by strict criteria, were not used for SLT. (16) Although our findings show the potential for a modest, but meaningful, opportunity to reduce wait-list mortality following greater use of SLT for children in select groups (eg, recipient weight <10 kg), there are likely several other downstream benefits as well. First, broader use of SLT would likely mean that many children could be transplanted at lower allocation scores, corresponding both to lower pretransplant morbidity and cost. Second, broader use of SLT for select groups of children would then allow for a greater number of whole organs to be available for other groups such as slightly larger children. At the same time, one limitation of our study is that we did not formally incorporate an analysis that combined pretransplant and posttransplant mortality (ie, survival benefit). However, given that we analyzed all-cause graft loss and there was no increase in graft failure for select recipients, it can be inferred that there is no increase in posttransplant mortality as well.
One important limitation of our study is that through SRTR, we do not have information about other meaningful outcomes such as biliary strictures and vascular thromboses. Similarly, we do not have specific information as to why some subgroups had higher rates of graft failure. The Studies in Pediatric Liver Transplantation Consortium published outcomes from 1995 to 2006 and identified both higher rates of graft failure as well as biliary strictures and vascular complications in children receiving technical variant grafts. (11) However, it is not clear if these complications currently exist at higher rates in SLT, especially given more recent reports that graft failure in SLT, both immediate and long term, is
Original article | 127 currently equivalent to WLT. (4) Reports from adult literature have been conflicting with some studies showing similar rates of biliary stricture and vascular thromboses, whereas other studies still showing higher rates of these surgical complications. (6, (17) (18) (19) Nonetheless, one likely explanation for higher rates of graft failure among certain groups is that they have higher rates of these well-established complications leading to graft failure.
A second limitation of our study is that it is derived from observational, as opposed to experimental, data. Randomized trials would be impractical, so observational studies represent the best opportunity to identify the benefit of different types of allografts. In this instance, it is possible that favorable outcomes seen in SLT are due to careful candidate selection on the part of health care teams. However, this potential for bias is not likely to impact our analysis because we have adjusted for many known characteristics associated with disease severity including both PELD/MELD, and therefore are making comparisons among people with similar health status. Nonetheless, residual confounding of disease severity may occur. A final limitation is that the sample size was very small for certain subcohorts (eg, weight >35 kg), making it hard to obtain a precise estimate for the relative impact of SLT versus WLT in these groups.
Although many considerations go into the decision to use SLT for a specific patient, there is clear agreement in the transplant community that demand for organs exceeds the supply and that minimization of pretransplant mortality risk should be the highest priority. In the context of demonstrably equivalent outcomes for adult recipients of SLT, our findings further support that greater use of SLT in the majority of recipients can address the problem of organ scarcity such that fewer children would die while awaiting an offer and still have acceptable outcomes after transplantation.
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